US mRNA medicine company Moderna (Nasdaq: MRNA) closed 13% higher on Thursday after surprising investors with its financial results.
The biotech firm currently only sells a COVID-19 vaccine, but still managed to make a profit in the fourth quarter of 2023.
"We look forward to the anticipated approvals of our RSV vaccine beginning in the first half of the year"Diluted earnings per share for the quarter came in at $0.55. While this was well down on the $3.81 of the final quarter of 2022, analysts surveyed by LSEG had expected a loss of $0.97.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze